Is Sanara Medtech Stock a Good Investment?
Sanara Medtech Investment Advice | SMTI |
- Examine Sanara Medtech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sanara Medtech's leadership team and their track record. Good management can help Sanara Medtech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Sanara Medtech's business and its evolving consumer preferences.
- Compare Sanara Medtech's performance and market position to its competitors. Analyze how Sanara Medtech is positioned in terms of product offerings, innovation, and market share.
- Check if Sanara Medtech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sanara Medtech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sanara Medtech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sanara Medtech is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Sanara Medtech Stock
Researching Sanara Medtech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 67.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.99. Sanara Medtech last dividend was issued on the 10th of May 2019. The entity had 1:100 split on the 10th of May 2019.
To determine if Sanara Medtech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sanara Medtech's research are outlined below:
| The company reported the previous year's revenue of 64.99 M. Net Loss for the year was (4.3 M) with profit before overhead, payroll, taxes, and interest of 70.38 M. | |
| Sanara Medtech currently holds about 12.68 M in cash with (3.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.53. | |
| Sanara Medtech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 |
Sanara Medtech Quarterly Good Will |
|
Sanara Medtech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sanara Medtech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sanara Medtech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Sanara Medtech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sanara Medtech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-16 | 2021-06-30 | -0.12 | -0.16 | -0.04 | 33 | ||
2023-11-13 | 2023-09-30 | -0.04 | -0.13 | -0.09 | 225 | ||
2023-08-14 | 2023-06-30 | -0.13 | -0.22 | -0.09 | 69 | ||
2021-11-12 | 2021-09-30 | -0.18 | -0.27 | -0.09 | 50 | ||
2024-03-25 | 2023-12-31 | -0.13 | -0.03 | 0.1 | 76 | ||
2023-03-20 | 2022-12-31 | -0.26 | -0.38 | -0.12 | 46 | ||
2024-05-13 | 2024-03-31 | -0.07 | -0.21 | -0.14 | 200 | ||
2022-11-14 | 2022-09-30 | -0.32 | -0.18 | 0.14 | 43 |
Know Sanara Medtech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sanara Medtech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sanara Medtech backward and forwards among themselves. Sanara Medtech's institutional investor refers to the entity that pools money to purchase Sanara Medtech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 15.9 K | Squarepoint Ops Llc | 2024-12-31 | 14.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 13.8 K | Jpmorgan Chase & Co | 2024-12-31 | 13.6 K | Bank Of New York Mellon Corp | 2024-12-31 | 13.1 K | Goldman Sachs Group Inc | 2024-12-31 | 12.3 K | Charles Schwab Investment Management Inc | 2024-12-31 | 11.4 K | Salem Investment Counselors Inc | 11.2 K | Stephens Inc | 2024-12-31 | 10.8 K | Blackrock Inc | 2024-12-31 | 215 K | Vanguard Group Inc | 2024-12-31 | 200.8 K |
Sanara Medtech's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 302.88 M.Market Cap |
|
Sanara Medtech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.09) |
Determining Sanara Medtech's profitability involves analyzing its financial statements and using various financial metrics to determine if Sanara Medtech is a good buy. For example, gross profit margin measures Sanara Medtech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sanara Medtech's profitability and make more informed investment decisions.
Evaluate Sanara Medtech's management efficiency
Sanara Medtech has return on total asset (ROA) of (0.0508) % which means that it has lost $0.0508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2028) %, meaning that it created substantial loss on money invested by shareholders. Sanara Medtech's management efficiency ratios could be used to measure how well Sanara Medtech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.07. As of now, Sanara Medtech's Total Current Assets are increasing as compared to previous years. The Sanara Medtech's current Intangible Assets is estimated to increase to about 54.2 M, while Non Currrent Assets Other are forecasted to increase to (16.3 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.85 | 5.09 | |
| Tangible Book Value Per Share | (0.43) | (0.45) | |
| Enterprise Value Over EBITDA | -1.1 K | -1 K | |
| Price Book Value Ratio | 6.83 | 7.17 | |
| Enterprise Value Multiple | -1.1 K | -1 K | |
| Price Fair Value | 6.83 | 7.17 | |
| Enterprise Value | 312.2 M | 176.8 M |
Understanding the operational decisions made by Sanara Medtech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.373 |
Basic technical analysis of Sanara Stock
As of the 21st of March, Sanara Medtech has the Coefficient Of Variation of (21,433), risk adjusted performance of 0.0028, and Variance of 8.35. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sanara Medtech, as well as the relationship between them.Sanara Medtech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sanara Medtech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sanara Medtech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sanara Medtech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sanara Medtech's Outstanding Corporate Bonds
Sanara Medtech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sanara Medtech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sanara bonds can be classified according to their maturity, which is the date when Sanara Medtech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Sanara Medtech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sanara Medtech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0028 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 2.12 | |||
| Coefficient Of Variation | (21,433) | |||
| Standard Deviation | 2.89 | |||
| Variance | 8.35 | |||
| Information Ratio | 0.0178 | |||
| Jensen Alpha | 0.0989 | |||
| Total Risk Alpha | 0.2204 | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 16.33 | |||
| Value At Risk | (4.59) | |||
| Potential Upside | 4.32 | |||
| Skewness | 0.7273 | |||
| Kurtosis | 2.38 |
| Risk Adjusted Performance | 0.0028 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 2.12 | |||
| Coefficient Of Variation | (21,433) | |||
| Standard Deviation | 2.89 | |||
| Variance | 8.35 | |||
| Information Ratio | 0.0178 | |||
| Jensen Alpha | 0.0989 | |||
| Total Risk Alpha | 0.2204 | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 16.33 | |||
| Value At Risk | (4.59) | |||
| Potential Upside | 4.32 | |||
| Skewness | 0.7273 | |||
| Kurtosis | 2.38 |
Consider Sanara Medtech's intraday indicators
Sanara Medtech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sanara Medtech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sanara Medtech Corporate Filings
F4 | 27th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 22nd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 15th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Sanara Stock media impact
Far too much social signal, news, headlines, and media speculation about Sanara Medtech that are available to investors today. That information is available publicly through Sanara media outlets and privately through word of mouth or via Sanara internal channels. However, regardless of the origin, that massive amount of Sanara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sanara Medtech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sanara Medtech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sanara Medtech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sanara Medtech alpha.
Sanara Medtech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sanara Medtech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sanara Medtech Corporate Management
| Bill Fitzgerald | Compliance Officer | Profile | |
| Jacob Waldrop | Chief Officer | Profile | |
| Callon Nichols | Director Relations | Profile | |
| Elizabeth Taylor | Chief Officer | Profile | |
| Jane Fore | Chief Officer | Profile | |
| Tricia Matteson | Director Marketing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth 0.352 | Return On Assets | Return On Equity |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sanara Medtech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.